


"I sleep well"



Twice daily

SEREVENT

salmeterol xinafoate

FOR ACTIVE DAYS AND RESTFUL NIGHTS

Serevent (salmeterol xinafoate)

Abridged Prescribing Information

(Please refer to the full data sheet before prescribing)

Uses Treatment of asthma (including nocturnal and exercise-induced) in patients requiring long-term regular bronchodilator therapy. Patients should normally also be receiving regular and adequate doses of inhaled anti-inflammatory agents, or oral corticosteroids. **Dosage and administration** For inhalation only. **Adults and children 4 years and over:** 50 micrograms twice daily. **Adults only:** More severe cases 100 micrograms twice daily. **Children below 4 years:** Not recommended at present.

Contra-indication Hypersensitivity. **Precautions** **Steroid therapy:** Serevent is not a replacement for corticosteroids and/or, in children, sodium cromoglycate. Warn patients not to stop or reduce such therapy. **Severe or unstable asthma:** Bronchodilators should not be the only or main treatment. Consider using oral steroids and/or

maximum doses of inhaled corticosteroids. Warn patients to seek medical advice if short-acting bronchodilator use increases or becomes less effective. Treat severe exacerbations in the normal way. **Acute symptoms:** Serevent is not for relief of acute symptoms. A short-acting inhaled bronchodilator is required. **Thyrotoxicosis:** Use with caution. **Drug interactions:** Avoid beta-blockers. **Hypokalaemia:** May occur, particularly in acute severe asthma. It may be potentiated by xanthine derivatives, steroids, diuretics and hypoxia. Monitor serum potassium levels in these situations. **Pregnancy and lactation:** Experience is limited. Balance risks against benefits. **Side effects** Tremor, subjective palpitations and headaches have been reported, but are usually mild and transient. Skin reactions, muscle cramps, non-specific chest pain, local irritation and arthralgia have been reported. Potentially serious hypokalaemia may result from β_2 -agonist therapy. **Paradoxical bronchospasm:**

Substitute alternative therapy. **Presentation and Basic NHS cost** **Serevent Diskhaler:** Pack of 14 four-place disk foils, together with a Serevent Diskhaler. 50 micrograms – £29.97. **Serevent Diskhaler refill pack:** Pack of 14 four-place disk foils only – £29.40. **Serevent Inhaler:** 120 actuations per inhaler. 25 micrograms – £28.60. Hospital packs are also available. **Product licence numbers** 0045/0158, 0045/0157.

POM



ALLEN & HANBURY'S

Further information is available on request from:

Allen & Hanburys Limited

Uxbridge, Middlesex UB11 1BT

Diskhaler and Serevent are trade marks of the Glaxo Group of Companies

September 1993

When introducing Serevent in adults we strongly recommend that you do not stop or reduce the dose of corticosteroids. Similarly, in children, do not stop or reduce corticosteroids or sodium cromoglycate.

Presentations: Pulmicort Respules (2 ml single dose unit ampoules) containing 0.25 mg/ml or 0.5 mg/ml budesonide in a suspension for nebulisation. **Uses:** Bronchial asthma where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. **Dosage and administration:** Dosage schedules: Administer from suitable nebulisers. Dose delivered to the patient varies depending on the nebulising equipment used (see data sheet). Adjust dosage individually. Initially during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids the recommended dose in adults (including elderly and children 12 years and older) is usually 1-2 mg twice daily. In very severe cases the dosage may be further increased. Children 3 months to 12 years: 0.5-1 mg twice daily. The maintenance dose should be the lowest dose which keeps the patient symptom-free. Recommended doses are: Adults (including elderly and children 12 years and older) 0.5-1 mg twice daily. Children (3 months to 12 years): 0.25-0.5 mg twice daily. For an increased therapeutic effect increase dose of Pulmicort rather than combine treatment with oral corticosteroids because of the lower risk of systemic effects. **Contra-indication:** Hypersensitivity to any of the constituents. **Special warnings and precautions:** Care is needed in patients with pulmonary tuberculosis and viral infections in the airways. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive

mucus in the bronchi. Transfer of patients dependent on oral steroids to Pulmicort demands special care; see data sheet for further details. The nebuliser chamber should be cleaned and dried after every administration. Pulmicort does not affect the ability to drive and use machines. Pulmicort Respules can be mixed with 0.9% saline and with solutions of terbutaline, salbutamol, sodium cromoglycate or ipratropium bromide. **Side effects:** Mild irritation in the throat, coughing and hoarseness and oral candidiasis have been reported; in rare cases inhaled drugs may provoke bronchoconstriction in hyperreactive patients. Facial skin should be washed after use of the face mask as irritation can occur. Coughing can usually be prevented by inhaling a β_2 agonist (e.g. terbutaline) 5-10 minutes before inhalation of Pulmicort Respules. Avoid in pregnancy. **Pharmaceutical precautions:** Store below 30°C. Use within 3 months of opening the foil envelope. Protect opened ampoule from light. Use within 12 hours of opening. **Legal category:** POM. **Basic NHS price:** Pulmicort Respules 0.25 mg/ml (20 single dose units): £32.00. Pulmicort Respules 0.5 mg/ml (20 single dose units): £44.64. **Product licence numbers:** Pulmicort Respules 0.25 mg/ml PL 0017/0309. Pulmicort Respules 0.5 mg/ml PL 0017/0310. **For further information contact the product licence holder:** Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH. **Reference:** 1. H gerbottam TW et al. Eur J Clin Res 1994; 5: 1-10.



Time to take a breather from oral steroids

Pulmicort[®]
BUDESONIDE
Respules[®]

A high-dose nebulised steroid that's low on side effects^{1†}

DECISIVE ACTION

Fortum/NaCl Intravenous Infusion Kit - Each kit contains 1 vial of ceftazidime, 50ml of 0.9% w/v Sodium Chloride Intravenous Infusion, transfer set, 100% alcohol injection swab, sealing cap and 100% alcohol swab. The treatment of choice for proven single and mixed infections caused by susceptible organisms. **Fortum/Saline Infusion Kit** - Each kit contains 1 vial of 2g ceftazidime for injection and administration set. (See Data Sheet for details.) 1g to 2g i.v. per day and by the i.p. route in 250mg per 2L dialysis fluid. Most infections: 2g i.v. b.i.d.; severe infections, 4-6g i.v. per day. Cystic fibrosis - up to 150mg/kg/day in three divided doses. Renal impairment should be reduced when creatinine clearance <50ml/min. An initial 1g loading dose may be given with severe renal insufficiency. **Elderly:** Usual dosage should not normally exceed 2g i.v. b.i.d. **Neonates/Infants/Children:** (See Data Sheet for details.) Up to two months: 25-50mg/kg/day as two divided doses. Over two months: 30 to 100mg/kg/day as two or three divided doses. Cystic fibrosis, meningitis, immunocompromised: up to 150mg/kg/day (max 6g daily) in three divided doses. Sensitivity results recommended before commencing meningitis monotherapy. The Infusion Kit, in the dosage presented, may not be appropriate for use in children. **Contra-indication** Known hypersensitivity to cephalosporins. **Precautions** Previous anaphylactic reaction to penicillin. Administer with caution in early pregnancy, infancy and with concurrent nephrotoxic drug treatment. Fortum is excreted in human milk in low concentrations. **Drug interactions** Possible interference with copper reduction methods may occur. Fortum and aminoglycosides should not be mixed in the same giving set or syringe. Prolonged use may cause overgrowth of non-susceptible organisms (e.g. candida, enterococci).

which may require interruption of treatment or other measures. **Side effects** Adverse reactions occur infrequently; pain and/or inflammation (i.m.) and phlebitis and/or thrombophlebitis (i.v.), rashes, fever, pruritus, anaphylaxis. GI disturbances, headache, dizziness, paraesthesia and bad taste. Transient changes in laboratory values may occur: eosinophilia, positive Coombs' test, thrombocytosis, leucopenia, neutropenia, thrombocytopenia and slight rises in hepatic enzymes. **Basic NHS cost** Packs of vials for injection (5 x 250mg, 5 x 500mg, 5 x 1g, 5 x 2g), and an infusion pack (5 x 2g); £9.90 per gram. **Fortum/Saline Infusion Kit; £20.82.** **Product licence numbers** Fortum for injection: 250mg: 0004/0304; 500mg: 0004/0292; 1g: 0004/0293; 2g: 0004/0294. Sodium Chloride Intravenous Infusion: 60/0015. **Product licence holder** Fortum for Injection: Glaxo Operations UK Limited, Greenford, Middlesex UB6 0HE. Sodium Chloride Intravenous Infusion: Glaxo Research Ltd, Craigavon, Northern Ireland BT63 5UA. **POM**

Glaxo

Further information is available on request from: Glaxo Laboratories Limited, Park Road, Uxbridge, Middlesex UB8 3PH. Tel: 081-990 9444. Fortum is a Glaxo trade mark. © September 1993



FORTUM ceftazidime

Proven success in serious infections



How do you...

Persuade a government to ban tobacco advertising?


Campaign against dumping of toxic waste?

Energise the fight against AIDS?



In *The Fight for Public Health*, Simon Chapman and Deborah Lupton show how lobbying through media advocacy can be a powerful tool in mobilising public support and getting public health legislation passed. Illustrated with photographs and crammed with compelling examples from around the world, this lively and entertaining guide:

- Describes what advocacy is
- Shows how public opinion has influenced public health policy in the past
- Includes an A-Z of strategies for gaining media attention.



"This splendid book moves the art of media advocacy a giant step forward.

Chapman and Lupton's counsel leapfrogs continents; it will be as welcome and applicable in London and Washington as in Sydney."

Michael Pertschuk, Director, The Advocacy Institute, Washington, DC

ISBN 0 7279 0849 9
200 Pages October 1994
UK £19.95; Overseas £22.00
(BMA members £18.95; £21.00)

BMJ
Publishing Group

ORDER FORM

Available from: BMJ Publishing Group, P.O. Box 295, London WC1H 9TE (Tel: 071 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House

Please send me _____ copy/ies of
THE FIGHT FOR PUBLIC HEALTH

Name _____
(Print Clearly)

Address _____

Postcode _____

BMA Membership No. _____

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS VISA MASTERCARD

Card No. _____ Exp _____

Signature _____

☐ Please send me a BMJ PUBLISHING GROUP CATALOGUE

In the USA contact American College of Physicians, tel: 800 523 1546; in Australia contact AMA Services (WA) PTY Ltd, Tel: 389 8288

A LIFE-SAVING SYSTEM FOR ASTHMATICS



Bricanyl[®]
✕ Turbohaler[®]
 TERBUTALINE SULPHATE

Pulmicort[®]
✕ Turbohaler[®] 200
 BUDESONIDE

Abridged prescribing information: **Presentation:** Bricanyl Turbohaler. Dry powder inhaler delivering 0.5 mg terbutaline sulphate per actuation. **Uses:** Relief and prevention of bronchospasm in bronchial asthma and bronchopulmonary disorders in which bronchospasm or reversible airways obstruction is a complicating factor. **Dosage and administration:** Adults and children (including elderly): One inhalation (0.5 mg) as required. Not more than 4 inhalations/day. **Contra-indications, warnings, etc:** Sensitivity to terbutaline sulphate. **Precautions:** Care should be taken in patients with myocardial insufficiency or thyrotoxicosis. Additional blood glucose measurements are initially recommended in diabetic patients. If treatment becomes less effective or shorter acting, the patient's general condition should be reviewed. Do not use in patients with hypertrophic cardiomyopathy. Potentially serious hypokalaemia may result from B2-agonist therapy. Administer with caution during the first trimester of pregnancy. Do not administer concurrently with non-selective B-blockers. Use with caution with other sympathomimetics. **Side effects:** Tremor, tonic cramp and palpitations are all characteristic of sympathomimetic amines. A few patients feel tense. **Basic NHS price:** Bricanyl Turbohaler (100 doses) £8.94. **Legal category:** POM. **Product licence number:** PL 0017/0241.

Presentations: Pulmicort Turbohaler 100. 100 µg/puff budesonide dry powder inhaler containing 200 doses. Pulmicort Turbohaler 200. 200 µg/puff budesonide dry powder

inhaler containing 100 doses. Pulmicort Turbohaler 400. 400 µg/puff budesonide dry powder inhaler containing 50 doses. **Uses:** Bronchial asthma. **Dosage and administration:** Individualise dose. Adults: 200-1600 µg daily in divided doses. Children: 200-800 µg daily in divided doses. Maintenance: Use lowest possible dose. Brush the teeth and rinse the mouth out with water after each use. **Contra-indications, warnings, etc:** Active pulmonary tuberculosis. Special care is needed in patients with fungal and viral infections in the airways. Avoid administration during pregnancy. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to treatment with Pulmicort demands special care. See data sheet for further details. **Side effects:** Mild irritation in the throat, hoarseness and oral candidiasis occur in some patients. Rare cases of cataract have been reported after prolonged use of corticosteroids. **Legal category:** POM. **Basic NHS price:** Pulmicort Turbohaler 100 (200 doses) £18.50. Pulmicort Turbohaler 200 (100 doses) £18.50. Pulmicort Turbohaler 400 (50 doses) £18.50. **Product licence numbers:** Pulmicort Turbohaler 100 PL 0017/0319 (100 µg/puff). Pulmicort Turbohaler 200 PL 0017/0272 (200 µg/puff). Pulmicort Turbohaler 400 PL 0017/0271 (400 µg/puff).

ASTRA
 Astra Pharmaceuticals

Further information is available from the product licence holder: Astra Pharmaceuticals Limited, Home Park, Kings Langley, Herts WD4 8DH. ©Registered trade mark

Date of preparation: April 1994